Filing Summary
Business Context and Reporting Period
SOPHiA GENETICS SA, a Swiss foreign private issuer, filed a Form 6-K for August 2021. The filing reports the completion of additional share issuance in connection with the company’s initial public offering (IPO).
Key Financial and Capital Markets Metrics
- On August 25, 2021, the company issued and sold 519,493 ordinary shares to IPO underwriters following their exercise of an option to purchase additional shares.
- Total IPO shares sold increased to 13,519,493.
- Total gross IPO proceeds were approximately $243.4 million, before underwriting discounts and commissions, fees, and offering expenses.
- The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or net proceeds after offering expenses.
Material Changes and Other Items
The underwriters’ option exercise increased the total number of shares sold and gross IPO proceeds relative to the initial offering. The filing also includes the amended Articles of Association as Exhibit 99.1.
Guidance, Outlook, Risks, and Contingencies
The filing does not provide operating guidance, management outlook, risk updates, contingencies, or unusual operating items. The reported proceeds are gross and do not reflect deductions for underwriting discounts, commissions, fees, or offering expenses.
Investor Verification Checklist
- Verify the final IPO share count of 13,519,493 ordinary shares.
- Verify the approximately $243.4 million gross proceeds and reconcile them to net proceeds after offering costs.
- Review the amended Articles of Association filed as Exhibit 99.1.
- Confirm the company’s post-IPO share count, capitalization, cash balance, and use of proceeds in subsequent filings.